Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/IIa Clinical Trial Assessing the Rapid Onset Characteristics of TLL-018 in Subjects With Moderate-to-Severe Chronic Spontaneous Urticaria Who Fail to Achieve Adequate Control With Second-Generation H1 Antihistamines

NCT07665996 is registered in ClinicalTrials.gov with Hangzhou Highlightll Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07665996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07665996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/IIa Clinical Trial Assessing the Rapid Onset Characteristics of TLL-018 in Subjects With Moderate-to-Severe Chronic Spontaneous Urticaria Who Fail to Achieve Adequate Control With Second-Generation H1 Antihistamines
Lead sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 15, 2026
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria (csu)